Medtronic PLC (NYSE:MDT) – Investment analysts at SunTrust Banks dropped their Q3 2017 EPS estimates for shares of Medtronic PLC in a research note issued to investors on Tuesday. SunTrust Banks analyst B. Nudell now expects that the brokerage will earn $1.11 per share for the quarter, down from their previous estimate of $1.14. SunTrust Banks also issued estimates for Medtronic PLC’s Q4 2017 earnings at $1.31 EPS, FY2017 earnings at $4.57 EPS, Q1 2018 earnings at $1.13 EPS, Q3 2018 earnings at $1.25 EPS, Q4 2018 earnings at $1.45 EPS, FY2018 earnings at $5.07 EPS, FY2019 earnings at $5.54 EPS and FY2020 earnings at $6.06 EPS.

A number of other equities research analysts have also weighed in on MDT. Deutsche Bank AG restated a “buy” rating on shares of Medtronic PLC in a report on Monday, October 31st. Jefferies Group lowered their price objective on shares of Medtronic PLC from $100.00 to $88.00 and set a “buy” rating for the company in a report on Wednesday. Oppenheimer Holdings Inc. lowered their price objective on shares of Medtronic PLC from $94.00 to $84.00 and set an “outperform” rating for the company in a report on Wednesday. BMO Capital Markets lowered their price objective on shares of Medtronic PLC from $94.00 to $87.00 and set an “outperform” rating for the company in a report on Wednesday. Finally, Barclays PLC lowered their price target on shares of Medtronic PLC from $93.00 to $85.00 and set an “overweight” rating for the company in a report on Wednesday. Seven equities research analysts have rated the stock with a hold rating and twenty have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $88.47.

Earnings History and Estimates for Medtronic PLC (NYSE:MDT)

ILLEGAL ACTIVITY NOTICE: “Analysts Set Expectations for Medtronic PLC’s Q3 2017 Earnings (MDT)” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another website, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this story can be read at https://www.thecerbatgem.com/2016/11/26/analysts-set-expectations-for-medtronic-plcs-q3-2017-earnings-mdt.html.

Medtronic PLC (NYSE:MDT) opened at 75.52 on Thursday. Medtronic PLC has a 1-year low of $71.03 and a 1-year high of $89.27. The company has a market capitalization of $104.36 billion, a price-to-earnings ratio of 29.39 and a beta of 1.01. The firm has a 50 day moving average of $81.84 and a 200-day moving average of $84.68.

Medtronic PLC (NYSE:MDT) last posted its quarterly earnings results on Tuesday, November 22nd. The medical technology company reported $1.12 EPS for the quarter, topping analysts’ consensus estimates of $1.11 by $0.01. The business earned $7.35 billion during the quarter, compared to analysts’ expectations of $7.46 billion. Medtronic PLC had a net margin of 14.63% and a return on equity of 12.36%. The business’s quarterly revenue was up 4.1% on a year-over-year basis. During the same period last year, the company posted $1.03 earnings per share.

A number of institutional investors have recently bought and sold shares of MDT. Exxonmobil Investment Management Inc. TX boosted its position in shares of Medtronic PLC by 6.3% in the second quarter. Exxonmobil Investment Management Inc. TX now owns 363,984 shares of the medical technology company’s stock valued at $31,583,000 after buying an additional 21,619 shares during the period. LVM Capital Management Ltd. MI acquired a new position in shares of Medtronic PLC during the second quarter valued at $217,000. Thompson Rubinstein Investment Management Inc. OR boosted its position in shares of Medtronic PLC by 1.3% in the second quarter. Thompson Rubinstein Investment Management Inc. OR now owns 50,693 shares of the medical technology company’s stock valued at $4,399,000 after buying an additional 665 shares during the period. Moreno Evelyn V boosted its position in shares of Medtronic PLC by 1.3% in the second quarter. Moreno Evelyn V now owns 70,520 shares of the medical technology company’s stock valued at $6,119,000 after buying an additional 912 shares during the period. Finally, Rosenbaum Jay D. boosted its position in shares of Medtronic PLC by 5.7% in the second quarter. Rosenbaum Jay D. now owns 15,225 shares of the medical technology company’s stock valued at $1,321,000 after buying an additional 815 shares during the period. Institutional investors and hedge funds own 81.25% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Analysts Set Expectations for Medtronic PLC’s Q3 2017 Earnings (MDT)” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another website, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this story can be read at https://www.thecerbatgem.com/2016/11/26/analysts-set-expectations-for-medtronic-plcs-q3-2017-earnings-mdt.html.

In other Medtronic PLC news, Director Kendall J. Powell sold 7,907 shares of the company’s stock in a transaction dated Thursday, September 15th. The shares were sold at an average price of $85.45, for a total transaction of $675,653.15. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Bryan C. Hanson sold 15,000 shares of the company’s stock in a transaction dated Monday, August 29th. The shares were sold at an average price of $87.00, for a total transaction of $1,305,000.00. Following the transaction, the executive vice president now owns 168,192 shares in the company, valued at approximately $14,632,704. The disclosure for this sale can be found here. Company insiders own 0.25% of the company’s stock.

Medtronic PLC Company Profile

Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.

5 Day Chart for NYSE:MDT

Receive News & Stock Ratings for Medtronic PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic PLC and related stocks with our FREE daily email newsletter.